The First Clinical Medical College, Lanzhou University, Lanzhou, 730000, China.
Department of Hepatobiliary Surgery, Affiliated Hospital of North Sichuan Medical College, Nanchong, 637600, China.
J Transl Med. 2024 Sep 30;22(1):875. doi: 10.1186/s12967-024-05664-z.
N-acetyltransferase 10 (NAT10) plays a crucial role in the occurrence and development of various tumors. However, the current regulatory mechanism of NAT10 in tumors is limited to its presence in tumor cells. Here, we aimed to reveal the role of NAT10 in intrahepatic cholangiocarcinoma (ICC) and investigate its effect on macrophage polarization in the tumor microenvironment (TME).
The correlation between NAT10 and ICC clinicopathology was analyzed using tissue microarray (TMA), while the effect of NAT10 on ICC proliferation was verified in vitro and in vivo. Additionally, the downstream target of NAT10, C-C motif chemokine ligand 2 (CCL2), was identified by Oxford Nanopore Technologies full-length transcriptome sequencing, RNA immunoprecipitation-quantitative polymerase chain reaction, and coimmunoprecipitation experiments. It was confirmed by co-culture that ICC cells could polarize macrophages towards M2 type through the influence of NAT10 on CCL2 protein expression level. Through RNA-sequencing, molecular docking, and surface plasmon resonance (SPR) assays, it was confirmed that berberine (BBR) can specifically bind CCL2 to inhibit ICC development.
High expression level of NAT10 was associated with poor clinicopathological manifestations of ICC. In vitro, the knockdown of NAT10 inhibited the proliferative activity of ICC cells and tumor growth in vivo, while its overexpression promoted ICC proliferation. Mechanically, by binding to CCL2 messenger RNA, NAT10 increased CCL2 protein expression level in ICC and their extracellular matrix, thereby promoting the proliferation of ICC cells and M2-type polarization of macrophages. BBR can target CCL2, inhibit ICC proliferation, and reduce M2-type polarization of macrophages.
NAT10 promotes ICC proliferation and M2-type polarization of macrophages by up-regulating CCL2, whereas BBR inhibits ICC proliferation and M2-type polarization of macrophages by inhibiting CCL2.
N-乙酰基转移酶 10(NAT10)在各种肿瘤的发生和发展中起着至关重要的作用。然而,目前 NAT10 在肿瘤中的调控机制仅限于其存在于肿瘤细胞中。在这里,我们旨在揭示 NAT10 在肝内胆管癌(ICC)中的作用,并研究其对肿瘤微环境(TME)中巨噬细胞极化的影响。
使用组织微阵列(TMA)分析 NAT10 与 ICC 临床病理的相关性,同时在体外和体内验证 NAT10 对 ICC 增殖的影响。此外,通过牛津纳米孔技术全长转录组测序、RNA 免疫沉淀-定量聚合酶链反应和共免疫沉淀实验确定了 NAT10 的下游靶标 C-C 基序趋化因子配体 2(CCL2)。通过共培养实验证实,ICC 细胞可以通过影响 CCL2 蛋白表达水平将巨噬细胞极化为 M2 型。通过 RNA 测序、分子对接和表面等离子体共振(SPR)实验证实,小檗碱(BBR)可以特异性结合 CCL2 抑制 ICC 的发展。
NAT10 的高表达水平与 ICC 的不良临床病理表现相关。体外,NAT10 的敲低抑制了 ICC 细胞的增殖活性和体内肿瘤生长,而过表达则促进了 ICC 的增殖。机制上,NAT10 通过与 CCL2 信使 RNA 结合,增加了 ICC 及其细胞外基质中 CCL2 蛋白的表达水平,从而促进了 ICC 细胞的增殖和巨噬细胞的 M2 型极化。BBR 可以靶向 CCL2,抑制 ICC 增殖,并减少巨噬细胞的 M2 型极化。
NAT10 通过上调 CCL2 促进 ICC 增殖和巨噬细胞 M2 型极化,而 BBR 通过抑制 CCL2 抑制 ICC 增殖和巨噬细胞 M2 型极化。